Kestra Private Wealth Services LLC Increases Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Kestra Private Wealth Services LLC boosted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 2.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 167,012 shares of the biopharmaceutical company’s stock after buying an additional 4,089 shares during the period. Kestra Private Wealth Services LLC’s holdings in Bristol-Myers Squibb were worth $9,446,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. AMF Tjanstepension AB boosted its stake in Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after purchasing an additional 39,419 shares during the period. Wedmont Private Capital lifted its holdings in shares of Bristol-Myers Squibb by 14.1% in the third quarter. Wedmont Private Capital now owns 8,095 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 999 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Bristol-Myers Squibb by 383.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 17,232 shares of the biopharmaceutical company’s stock valued at $892,000 after acquiring an additional 13,664 shares during the period. Valeo Financial Advisors LLC grew its stake in Bristol-Myers Squibb by 6.2% during the third quarter. Valeo Financial Advisors LLC now owns 49,733 shares of the biopharmaceutical company’s stock valued at $2,573,000 after acquiring an additional 2,925 shares in the last quarter. Finally, Ritholtz Wealth Management lifted its stake in Bristol-Myers Squibb by 81.0% in the 3rd quarter. Ritholtz Wealth Management now owns 23,843 shares of the biopharmaceutical company’s stock worth $1,234,000 after purchasing an additional 10,669 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BMY. Citigroup upped their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research note on Wednesday, November 13th. Cantor Fitzgerald boosted their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a research note on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price on the stock. Finally, Morgan Stanley boosted their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Trading Down 0.8 %

NYSE BMY opened at $56.96 on Monday. The stock has a 50-day moving average of $57.56 and a 200-day moving average of $53.83. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10. The firm has a market cap of $115.51 billion, a PE ratio of -12.89, a price-to-earnings-growth ratio of 2.13 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.75 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 4.35%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.